Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code AGR

16. Specific lobbying issues

Climate Change
---H.R.2820/S.1251: The Growing Climate Solutions Act of 2021
---H.R.5376: Build Back Better Act of 2021
---FY 2022 Appropriations
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Fighting Climate Change through Biotechnology Innovation

Foreign Agricultural Biotechnology Laws and Regulations
---China Biotechnology Regulations
---Mexico Draft Decree Banning Genetically Modified Corn
---Mexico Import Approval Delays of Ag Biotech

Funding for the USDA
---FY 2022 Appropriations
---H.R.5376: Build Back Better Act of 2021

Genetically Engineered (GE) Animals
---H.R.133: Consolidated Appropriations Act for FY 2021
------GE Salmon Language in Sec. 778
---H.R.273 Prevention of Escapement of Genetically Altered Salmon in the United States Act.
---H.R.6119: Further Extending Government Funding Act
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Efficient Science-Based Review of Biotech Products
---Farm Bill Reauthorization
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering

Genetically Engineered (GE) Plants
---Climate Issues & impact on the agriculture, food, and forestry sectors
---EPA Regulatory Approach to Gene Editing
---EPA proposed revisions to regulations related to the oversight of certain plant-incorporated protectants (PIPs)

USDA/APHIS Agricultural Biotechnology Regulations
---The Sustainable, Ecological, Consistent, Uniform, Responsible, Efficient (SECURE) Rule under the Plant Protection Act
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Farm Bill Reauthorization
---Regulatory Treatment of Gene Edited Products
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), U.S. Trade Representative (USTR), White House Office, Food & Drug Administration (FDA), Environmental Protection Agency (EPA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ANI

16. Specific lobbying issues

Genetically Engineered (GE) Animals
---H.R.133: Consolidated Appropriations Act for FY 2021
------GE Salmon Language in Sec. 778
---H.R.273 Prevention of Escapement of Genetically Altered Salmon in the United States Act.
---H.R. 6119 Further Extending Government Funding Act
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Efficient Science-Based Review of Biotech Products
---Farm Bill Reauthorization
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

Coronavirus (COVID-19) Pandemic
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.5376: Build Back Better Act of 2021
---H.R.6119: Further Extending Government Funding Act

Funding for Antimicrobial Resistance (AMR) Programs
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.3932/S.2076: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR)
---H.R.4127: DISARM Act
---H.R.6119: Further Extending Government Funding Act
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.5376: Build Back Better Act of 2021
---H.R.6119: Further Extending Government Funding Act
---Funding for Strategic National Stockpile
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020

Funding for Biofuels, Biomass Crop Assistance, and Biorefineries
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.5376: Build Back Better Act of 2021
---H.R.6119: Further Extending Government Funding Act
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Incentives for Sustainable Aviation Fuels

Funding for Biorefineries
---FY 2022 Appropriations
---Climate Issues & impact on the agriculture, food, and forestry sectors

Funding for FDA
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.6119: Further Extending Government Funding Act
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Prescription Drug User Fee Act (PDUFA) VI
---Prescription Drug User Fee Act (PDUFA) VII Priorities

Funding for Health Resources and Services Administration (HRSA)
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.6119: Further Extending Government Funding Act

Funding for National Institutes of Health
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.6119: Further Extending Government Funding Act
---Advanced Research Projects Agency for Health (ARPA-H)

Funding for Renewable Chemicals/Bio-based Products
---FY 2022 Appropriations
---H.R.5376: Build Back Better Act of 2021

Funding for the Centers for Disease Control and Prevention Vaccine Programs
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.6119: Further Extending Government Funding Act
---Funding for 2022-2023 Influenza Season Preparedness and Response
---Funding for Routine Immunization Infrastructure during Pandemic
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020

Funding for the HHS Office of Infectious Disease and HIV/AIDS Policy
---FY 2022 Appropriations

Funding for the USDA
---FY 2022 Appropriations
---H.R.5376: Build Back Better Act of 2021

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), White House Office, Natl Institutes of Health (NIH)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CHM

16. Specific lobbying issues

Funding for Renewable Chemicals/Bio-based Products
---FY 2022 Appropriations
---H.R.5376: Build Back Better Act of 2021

Renewable Chemicals/Bio-based Products (Non-Funding)
---FY 2022 Appropriations
---H.R.5376: Build Back Better Act of 2021
---Climate Issues & impact on the agriculture, food, and forestry sectors

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Antitrust Legislation
---S.225: Competition and Antitrust Law Enforcement Reform Act of 2021

Bayh-Dole Act/Tech Transfer
---Bayh-Dole Act
---Domestic Manufacturing Requirement
---March-In Rights

Compulsory Licensing
---H.R.2148/S.909: Prescription Drug Price Relief Act
---H.R.4811: Medicare Negotiation and Competitive Licensing Act

Coronavirus (COVID-19) Pandemic
---Restrictions on Intellectual Property Rights
---TRIPS Waiver

Diversity in Patenting
---H.R.1723/S.632: Inventor Diversity for Economic Advancement (IDEA) Act of 2021

Drug Patenting
---H.R.153: Protecting Consumer Access to Generic Drugs Act of 2021
---H.R.2873/S.1435: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
---H.R.2883/S.1485: Stop Stalling Access to Affordable Medications
---H.R.2884/S.1435: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2021
---H.R.2891/S.1428: Preserve Access to Affordable Generics and Biosimilars Act
---H.R.4811: Medicare Negotiation and Competitive Licensing Act
---S.1435: Affordable Prescriptions for Patients Act of 2021
---Restrictions on Intellectual Property Rights

Intellectual Property Enforcement
---China
---General Patent Reform
---TRIPS Waiver

Inter Partes Review
---S.2774: Pride in Patent Ownership Act
---S.2891: Restoring the America Invents Act
---Support Technology and Research for Our Nations Growth and Economic Resilience (STRONGER) Patents Act (Discussion Draft)

Patent Reform
---S.1260: United States Innovation and Competition Act of 2021
------Ownership and Assignments of Patents

Patenting of Biological Inventions
---35 USC Section 101 on Patent Eligibility
---Section 101 Modernization

Patenting of Humanitarian Technologies
---H.R.5796: Patents for Humanity Act of 2021

US-China Trade Agreement
---IP Provisions

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Patent & Trademark Office (PTO), White House Office, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Natl Economic Council (NEC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ENG

16. Specific lobbying issues

Biofuels (Non-Funding)
---FY 2022 Appropriations
---H.R.3440/S.2263: Sustainable Skies Act of 2021
---H.R.5376: Build Back Better Act of 2021
---A Clean Fuel Standard or Low Carbon Fuel Standard
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Incentives for Sustainable Aviation Fuels
---Sustainable Aviation Fuels Tax Credit

Biomass Programs (Non-Funding)
---Climate Issues & impact on the agriculture, food, and forestry sectors

Biorefineries (Non-Funding)
---Climate Issues & impact on the agriculture, food, and forestry sectors

Climate Change
---FY 2022 Appropriations
---H.R.2820/S.1251: The Growing Climate Solutions Act of 2021
---H.R.5376: Build Back Better Act of 2021
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Fighting Climate Change through Biotechnology Innovation

Funding for Biofuels, Biomass Crop Assistance, and Biorefineries
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.5376: Build Back Better Act of 2021
---H.R.6119: Further Extending Government Funding Act
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Incentives for Sustainable Aviation Fuels

Renewable Fuel Standard (RFS)
---FY 2022 Appropriations
---A Clean Fuel Standard or Low Carbon Fuel Standard
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Proposed Rule to set 2021 Renewable Volume Obligations (RVOs) under the Renewable Fuel Standard and the 2022 RVO for Biomass-based Diesel

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code FOO

16. Specific lobbying issues

Genetically Engineered (GE) Animals
---H.R.133: Consolidated Appropriations Act for FY 2021
------GE Salmon Language in Sec. 778
---H.R.273 Prevention of Escapement of Genetically Altered Salmon in the United States Act.
---H.R.6119: Further Extending Government Funding Act
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Efficient Science-Based Review of Biotech Products
---Farm Bill Reauthorization
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code FUE

16. Specific lobbying issues

Biofuels (Non-Funding)
---FY 2022 Appropriations
---H.R.3440/S.2263: Sustainable Skies Act of 2021
---H.R.5376: Build Back Better Act of 2021
---A Clean Fuel Standard or Low Carbon Fuel Standard
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Incentives for Sustainable Aviation Fuels
---Sustainable Aviation Fuels Tax Credit

Biomass Programs (Non-Funding)
---Climate Issues & impact on the agriculture, food, and forestry sectors

Biorefineries (Non-Funding)
---Climate Issues & impact on the agriculture, food, and forestry sectors

Climate Change
---FY 2022 Appropriations
---H.R.2820/S.1251: The Growing Climate Solutions Act of 2021
---H.R.5376: Build Back Better Act of 2021
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Fighting Climate Change through Biotechnology Innovation

Funding for Biofuels, Biomass Crop Assistance, and Biorefineries
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.5376: Build Back Better Act of 2021
---H.R.6119: Further Extending Government Funding Act
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Incentives for Sustainable Aviation Fuels

Renewable Fuel Standard (RFS)
---FY 2022 Appropriations
---A Clean Fuel Standard or Low Carbon Fuel Standard
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Proposed Rule to set 2021 Renewable Volume Obligations (RVOs) under the Renewable Fuel Standard and the 2022 RVO for Biomass-based Diesel

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

21st Century Cures Act 2.0
---H.R.6000: Cures 2.0 Act

340B Drug Discount Program
---H.R.5376: Build Back Better Act of 2021
---Program Implementation & Oversight

Biodefense Research, Development and Procurement Issues (Non-Funding)
---American Pandemic Preparedness Plan (AP3)
---Executive Order on Modernizing Influenza Vaccines
---Implementation of 21st Century Cures Act of 2016
---Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act of 2019
---White House National Biodefense Strategy

Biosimilars
---H.R.2815: BIO SIM Act
---H.R.5376: Build Back Better Act of 2021
---Biosimilar Copay
---BSUFA Negotiations
---Reimbursement

Coronavirus (COVID-19) Pandemic
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.834: Pandemics Require Evaluating, Planning, And Responding Effectively (PREPARE) Act
---H.R.5237/H.R.5260: Reduced Costs and Continued Cures Act
---H.R.6119: Further Extending Government Funding Act
---S.2327: Seniors Prescription Drug Relief Act
---COVID-19 Lessons Learned
---COVID-19 Pricing-Related Provisions
---COVID-19 Vaccine Distribution
---Defense Production Act (DPA)
---Drug Supply Chain Management
---Healthcare Disparities
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---In-Home Administration of Part B Drugs
---Medicare Reimbursement Policies
---Monoclonal Antibody Coverage and Utilization
---Patient Cost-Sharing and Smoothing
---PREP Act COVID-19 Declaration Coverage for Private Sector Procurement
---R&D Funding for Medical Countermeasures
---Restrictions on Intellectual Property Rights
---Senate HELP Pandemic Preparedness White Paper
---Supply Chain Issues
---TRIPS IP Waiver

Diversity & Inclusion
---H.R.729: Strength in Diversity Act of 2021
---H.R.3085: Equity in Neuroscience and Alzheimer's Clinical Trials (ENACT) Act of 2021
---Clinical Trial Diversity
---Diverse and Equitable Participation in Clinical Trials (DEPICT) Act (Discussion Draft)

Drug Evaluation and Review
---S.1644: Promising Pathway Act
---COVID-19 Lessons Learned
---Compassionate Use/Expanded Access
---Expedited Pathways
---Implementation of the Prescription Drug User Fee Act (PDUFA) VI
---Innovation Incentives
---Patient-Focused Drug Development
---Prescription Drug User Fee Act (PDUFA) VII Priorities
---Priority Review Voucher Programs
---Regulatory Reform & Modernization
---Use of Real-World Evidence

Drug Importation
---H.R.4811: Medicare Negotiation and Competitive Licensing Act

Drug Manufacturing, Quality & Distribution
---H.R.7767: A bill to amend the Internal Revenue Code of 1986 to provide for credits against tax for domestic medical and drug manufacturing and advanced medical manufacturing equipment.
---Drug Shortages
---Executive Order on Buy American
---Inspections
---Pharmacy Compounding & Oversight
---Supply Chain Integrity and Traceability

Drug Patenting
---H.R.153: Protecting Consumer Access to Generic Drugs Act of 2021
---H.R.2873/S.1435: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
---H.R.2883/S.1485: Stop Stalling Access to Affordable Medications
---H.R.2884/S.1435: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2021
---H.R.2891/S.1428: Preserve Access to Affordable Generics and Biosimilars Act
---H.R.4811: Medicare Negotiation and Competitive Licensing Act
---S.1435: Affordable Prescriptions for Patients Act of 2021
---Restrictions on Intellectual Property Rights

Drug Pricing
---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
---H.R.19/S.2164: Lower Costs, More Cures Act of 2021
---H.R.2071: Medicare Prescription Drug Price Negotiation Act of 2021
---H.R.2139/S.908: Medicare Drug Price Negotiation Act
---H.R.2148/S.909: Prescription Drug Price Relief Act
---H.R.4811: Medicare Negotiation and Competitive Licensing Act
---H.R.5376: Build Back Better Act of 2021
---S.1388: Prescription Pricing for the People Act of 2021
---S.1435: Affordable Prescriptions for Patients Act of 2021
---CMMI Authority
---COVID-19 Pricing-Related Provisions
---Senate Finance Committee Drug Pricing Principles

Funding for Antimicrobial Resistance (AMR) Programs
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.3932/S.2076: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR)
---H.R.4127: DISARM Act
---H.R.6119: Further Extending Government Funding Act
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.5376: Build Back Better Act of 2021
---H.R.6119: Further Extending Government Funding Act
---Funding for Strategic National Stockpile
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020

Funding for FDA
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.6119: Further Extending Government Funding Act
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Prescription Drug User Fee Act (PDUFA) VI
---Prescription Drug User Fee Act (PDUFA) VII Priorities

Funding for Health Resources and Services Administration (HRSA)
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.6119: Further Extending Government Funding Act

Funding for National Institutes of Health
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.6119: Further Extending Government Funding Act
---Advanced Research Projects Agency for Health (ARPA-H)

Funding for the Centers for Disease Control and Prevention Vaccine Programs
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.6119: Further Extending Government Funding Act
---Funding for 2022-2023 Influenza Season Preparedness and Response
---Funding for Routine Immunization Infrastructure during Pandemic
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020

Funding for the HHS Office of Infectious Disease and HIV/AIDS Policy
---FY 2022 Appropriations

Generic Drug Entry
---H.R.2883: Stop Stalling Access to Affordable Medications Act

Medicaid
---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
---H.R.2139/S.908: Medicare Drug Price Negotiation Act
---H.R.2170/S.581: Helping Adults Protect Immunity (HAPI) Act of 2021
---H.R.5125: Strengthening Innovation in Medicare and Medicaid Act
---H.R.5376: Build Back Better Act of 2021
---Alternative Payment Arrangements for Gene Therapies
---Average Manufacturer Price Calculations
---Drug Benefit Design
---Pricing and Rebates
---Value-Based Purchasing (VBP) Rule

Opioid Crisis
---FDA Reforms

Orphan Drug Issues
---H.R.1629: Fairness in Orphan Drug Exclusivity Act
---H.R.5376: Build Back Better Act of 2021
---Tax Credit

Reimbursement and Coverage of Innovative Products
---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
---H.R.19/S.2164: Lower Costs, More Cures Act of 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.6119: Further Extending Government Funding Act
---H.R.2071: Medicare Prescription Drug Price Negotiation Act of 2021
---H.R.2139/S.908: Medicare Drug Price Negotiation Act
---H.R.2148/S.909: Prescription Drug Price Relief Act
---H.R.5237/H.R.5260: Reduced Costs and Continued Cures Act
---H.R.5376: Build Back Better Act of 2021
---S.2327: Seniors Prescription Drug Relief Act
---Administration Rebate Rule
---CMMI Authority
---Patient Cost-Sharing and Smoothing
---Value-Based Purchasing (VBP) Rule

Vaccines and Infectious Diseases
---FY 2022 Appropriations
---H.R.951/H.R.959/S.345/S.346: Maternal Vaccinations Act of 2021
---H.R.1978/S.912: Protecting Seniors through Immunizations Act of 2021
---H.R.2170/S.581: Helping Adults Protect Immunity (HAPI) Act of 2021
---H.R.2347/S.2691: Strengthening the Vaccines for Children Program Act of 2021
---H.R.3655: Vaccine Injury Compensation Modernization Act of 2021
---H.R.3932/S.2076: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR)
---H.R.4127: DISARM Act
---H.R.5376: Build Back Better Act of 2021
---S.4509: Vaccine and Coverage Certainty (VACC) Act
---Adult Immunization
---MCM Manufacturing & Capacity
---MCM R&D Incentives
---Monoclonal Antibody Coverage and Utilization
---Vaccine and Antimicrobial Resistance Product Development and Incentives
---Vaccine Injury Compensation Program

Vaccine Injury Compensation Program
---FY 2022 Appropriations
---H.R.3656: Vaccine Access Improvement Act of 2021
---S.3087: Vaccine Access Improvement Act of 2021
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Families First Coronavirus Response Act of 2020

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), White House Office, Natl Institutes of Health (NIH), U.S. Trade Representative (USTR), Office of Science & Technology Policy (OSTP), Office of Management & Budget (OMB), Centers For Disease Control & Prevention (CDC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HOM

16. Specific lobbying issues

Biodefense Research, Development and Procurement Issues (Non-Funding)
---American Pandemic Preparedness Plan (AP3)
---Executive Order on Modernizing Influenza Vaccines
---Implementation of 21st Century Cures Act of 2016
---Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act of 2019
---White House National Biodefense Strategy

Funding for Antimicrobial Resistance (AMR) Programs
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.3932/S.2076: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR)
---H.R.4127: DISARM Act
---H.R.6119: Further Extending Government Funding Act
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.5376: Build Back Better Act of 2021
---H.R.6119: Further Extending Government Funding Act
---Funding for Strategic National Stockpile
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MED

16. Specific lobbying issues

Biodefense Research, Development and Procurement Issues (Non-Funding)
---American Pandemic Preparedness Plan (AP3)
---Executive Order on Modernizing Influenza Vaccines
---Gene Editing
---Implementation of 21st Century Cures Act of 2016
---Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act of 2019
---White House National Biodefense Strategy

Coronavirus (COVID-19) Pandemic
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.6119: Further Extending Government Funding Act
---H.R.8080: Health STATISTICS Act of 2020
---Coronavirus Emerging Growth Companies (EGC) Extension Act (Discussion Draft)
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Immunization Information Systems
---R&D Funding for Medical Countermeasures
---Senate HELP Pandemic Preparedness White Paper

Funding for Antimicrobial Resistance (AMR) Programs
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.3932/S.2076: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR)
---H.R.4127: DISARM Act
---H.R.6119: Further Extending Government Funding Act
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.5376: Build Back Better Act of 2021
---H.R.6119: Further Extending Government Funding Act
---Funding for Strategic National Stockpile
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020

Funding for National Institutes of Health
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.6119: Further Extending Government Funding Act
---Advanced Research Projects Agency for Health (ARPA-H)

Funding for the Centers for Disease Control and Prevention Vaccine Programs
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.6119: Further Extending Government Funding Act
---Funding for 2022-2023 Influenza Season Preparedness and Response
---Funding for Routine Immunization Infrastructure during Pandemic
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Centers For Disease Control & Prevention (CDC), Natl Institutes of Health (NIH), Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

21st Century Cures Act 2.0
---H.R.6000: Cures 2.0 Act

340B Drug Discount Program
---H.R.5376: Build Back Better Act of 2021
---Program Implementation & Oversight

Coronavirus (COVID-19) Pandemic
---H.R.5237/H.R.5260: Reduced Costs and Continued Cures Act
---S.2327: Seniors Prescription Drug Relief Act
---Patient Cost-Sharing and Smoothing

Drug Pricing
---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
---H.R.19/S.2164: Lower Costs, More Cures Act of 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.2071: Medicare Prescription Drug Price Negotiation Act of 2021
---H.R.2139/S.908: Medicare Drug Price Negotiation Act
---H.R.2148/S.909: Prescription Drug Price Relief Act
---H.R.4811: Medicare Negotiation and Competitive Licensing Act;H.R.5376
---H.R.5376: Build Back Better Act of 2021
---H.R.6119: Further Extending Government Funding Act
---CMMI Authority
---COVID-19 Pricing-Related Provisions

Medicaid
---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
---H.R.2139/S.908: Medicare Drug Price Negotiation Act
---H.R.2170/S.581: Helping Adults Protect Immunity (HAPI) Act of 2021
---H.R.5125: Strengthening Innovation in Medicare and Medicaid Act
---H.R.5376: Build Back Better Act of 2021
---Alternative Payment Arrangements for Gene Therapies
---Average Manufacturer Price Calculations
---Drug Benefit Design
---Pricing and Rebates
---Value-Based Purchasing (VBP) Rule

Reimbursement and Coverage of Innovative Products
---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
---H.R.19/S.2164: Lower Costs, More Cures Act of 2021
---H.R.2071: Medicare Prescription Drug Price Negotiation Act of 2021
---H.R.2139/S.908: Medicare Drug Price Negotiation Act
---H.R.2148/S.909: Prescription Drug Price Relief Act
---H.R.5237/H.R.5260: Reduced Costs and Continued Cures Act
---S.2327: Seniors Prescription Drug Relief Act
---Administration Rebate Rule
---CMMI Authority
---Drug Pricing Provisions
---Patient Cost-Sharing and Smoothing
---Value-Based Purchasing (VBP) Rule

Vaccines and Infectious Diseases
---FY 2022 Appropriations
---H.R.1978/S.912: Protecting Seniors through Immunizations Act
---H.R.2170/S.581: Helping Adults Protect Immunity (HAPI) Act of 2021
---H.R.3932/S.2076: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR)
---H.R.4127: DISARM Act
---H.R.5376: Build Back Better Act of 2021

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office, Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code SMB

16. Specific lobbying issues

Capital Formation Incentives
---H.R.5376: Build Back Better Act of 2021
---H.R.7555: A bill to amend the Internal Revenue Code of 1986 to add a new medical research component to the credit for increasing research activities.
---H.R. 7556: A bill to amend the Internal Revenue Code of 1986 to make a portion of research credit refundable for certain small businesses engaging in specified medical research.
---Incentives for Sustainable Aviation Fuels
---Proposed amendments under the Exchange Act of 1934
---Proposed amendments under the Investment Company Act of 1940
---Proposed amendments under the Securities Act of 1933

Proxy Advisory Services
---Impact of Policies on Small Public Companies

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

Biofuels (Non-Funding)
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---H.R.5376: Build Back Better Act of 2021
---Incentives for Sustainable Aviation Fuels
---Sustainable Aviation Fuels Tax Credit

Capital Formation Incentives
---H.R.5376: Build Back Better Act of 2021
---H.R.7555: A bill to amend the Internal Revenue Code of 1986 to add a new medical research component to the credit for increasing research activities
---H.R. 7556: A bill to amend the Internal Revenue Code of 1986 to make a portion of research credit refundable for certain small businesses engaging in specified medical research.
---Incentives for Sustainable Aviation Fuels
---Proposed amendments under the Exchange Act of 1934
---Proposed amendments under the Investment Company Act of 1940
---Proposed amendments under the Securities Act of 1933

Coronavirus (COVID-19) Pandemic
---H.R.3623: IGNITE American Innovation Act

Orphan Drug Issues
---H.R.5376: Build Back Better Act of 2021
---Tax Credit

Qualified Small Business Stock (QSBS)
---H.R.5376: Build Back Better Act of 2021

Renewable Chemicals/Bio-based Products (Non-Funding)
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Investment Tax Credit
---Production Tax Credit

Research & Development Tax Credit Reforms
---H.R.7767: A bill to amend the Internal Revenue Code of 1986 to provide for credits against tax for domestic medical and drug manufacturing and advanced medical manufacturing equipment.
---Expensing of R&D Expenditures

Vaccine Injury Compensation Program
---FY 2022 Appropriations
---H.R.3656: Vaccine Access Improvement Act of 2021
---S.3087: Vaccine Access Improvement Act of 2021
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Families First Coronavirus Response Act of 2020

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

Digital Trade
---EU Digital Strategy

Drug Importation
---H.R.4811: Medicare Negotiation and Competitive Licensing Act

Drug Pricing
---Drug Pricing Issues in Japan

Foreign Agricultural Biotechnology Laws and Regulations
---China Biotechnology Regulations
---Mexico Draft Decree Banning Genetically Modified Corn
---Mexico Import Approval Delays of Ag Biotech

Intellectual Property International Enforcement
---China
---TRIPS Waiver

US-China Trade Agreement
---Ag-Biotech Provisions
---IP Provisions

World Trade Organization
---TRIPS Waiver

World Health Organization (WHO)
---TRIPS Waiver

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Agriculture - Dept of (USDA), White House Office, Health & Human Services - Dept of (HHS), Centers For Disease Control & Prevention (CDC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
No Yes